Stella Pharma Corporation (TYO:4888)
Japan
· Delayed Price · Currency is JPY 397.00
-4.00 (-1.00%)
Mar 19, 2025, 3:30 PM JST
Stella Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 |
| Revenue | 323 | 269 | 229 | 100 | 205 | - | Upgrade
|
| Revenue Growth (YoY) | 27.17% | 17.47% | 129.00% | -51.22% | - | - | Upgrade
|
| Cost of Revenue | 48 | 52 | 22 | 15 | 24 | - | Upgrade
|
| Gross Profit | 275 | 217 | 207 | 85 | 181 | - | Upgrade
|
| Selling, General & Admin | 537 | 571 | 625 | 555 | 539 | 951 | Upgrade
|
| Research & Development | 393 | 393 | 374 | 255 | 307 | - | Upgrade
|
| Operating Expenses | 943 | 977 | 1,013 | 826 | 862 | 951 | Upgrade
|
| Operating Income | -668 | -760 | -806 | -741 | -681 | -951 | Upgrade
|
| Interest Expense | -3 | -2 | -2 | -3 | -3 | - | Upgrade
|
| Interest & Investment Income | - | 1 | 1 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 6 | - | 31 | -20 | 27 | -9 | Upgrade
|
| Pretax Income | -665 | -761 | -776 | -764 | -657 | -960 | Upgrade
|
| Income Tax Expense | 2 | 2 | 2 | 3 | 2 | 2 | Upgrade
|
| Net Income | -667 | -763 | -778 | -767 | -659 | -962 | Upgrade
|
| Net Income to Common | -667 | -763 | -778 | -767 | -659 | -962 | Upgrade
|
| Shares Outstanding (Basic) | 33 | 31 | 29 | 28 | 20 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 33 | 31 | 29 | 28 | 20 | 16 | Upgrade
|
| Shares Change (YoY) | 7.01% | 7.27% | 2.83% | 40.17% | 28.43% | 20.37% | Upgrade
|
| EPS (Basic) | -20.41 | -24.63 | -26.94 | -27.31 | -32.89 | -61.67 | Upgrade
|
| EPS (Diluted) | -20.41 | -24.63 | -26.94 | -27.31 | -32.89 | -61.67 | Upgrade
|
| Free Cash Flow | - | -886 | -853 | -1,127 | -793 | - | Upgrade
|
| Free Cash Flow Per Share | - | -28.60 | -29.54 | -40.13 | -39.58 | - | Upgrade
|
| Gross Margin | 85.14% | 80.67% | 90.39% | 85.00% | 88.29% | - | Upgrade
|
| Operating Margin | -206.81% | -282.53% | -351.97% | -741.00% | -332.20% | - | Upgrade
|
| Profit Margin | -206.50% | -283.64% | -339.74% | -767.00% | -321.46% | - | Upgrade
|
| Free Cash Flow Margin | - | -329.37% | -372.49% | -1127.00% | -386.83% | - | Upgrade
|
| EBITDA | -633 | -725 | -771 | -707 | -650 | - | Upgrade
|
| EBITDA Margin | -195.98% | -269.52% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 35 | 35 | 35 | 34 | 31 | - | Upgrade
|
| EBIT | -668 | -760 | -806 | -741 | -681 | -951 | Upgrade
|
| EBIT Margin | -206.81% | -282.53% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.